Gene Polymorphisms Involved in Manifestation of Leucopenia, Digestive Intolerance, and Pancreatitis in Azathioprine-Treated Patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16370%2F12%3A43871450" target="_blank" >RIV/62157124:16370/12:43871450 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s10620-012-2163-y" target="_blank" >http://dx.doi.org/10.1007/s10620-012-2163-y</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s10620-012-2163-y" target="_blank" >10.1007/s10620-012-2163-y</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Gene Polymorphisms Involved in Manifestation of Leucopenia, Digestive Intolerance, and Pancreatitis in Azathioprine-Treated Patients

Popis výsledku v původním jazyce

Approximately 10-28 % of patients experience adverse drug reactions related to treatment with thiopurines. The most serious reaction is myelosuppression, typically manifested as leucopenia, which occurs in approximately 2-5 % of patients. Other adverse drug reactions that often accompany thiopurine therapy are pancreatitis, hepatotoxicity, allergic reactions, digestive intolerance, arthralgia, febrile conditions, and rash. The objective of this study was to assess the relationship between variant alleles of thiopurine S-methyltransferase (SNPs 238G } C, 460G } A and 719A } G), inosine triphosphate diphosphatase (SNPs 94C } A and IVS2 + 21A } C), and xanthine dehydrogenase (837C } T) and the occurrence of adverse drug reactions to azathioprine therapy.Genotype was determined for 188 Caucasians diagnosed with inflammatory bowel disease treated with a standard dose of azathioprine (1.4-2.0 mg/kg/day). Variant genotype thiopurine S-methyltransferase predisposes to development of leucopeni

Název v anglickém jazyce

Gene Polymorphisms Involved in Manifestation of Leucopenia, Digestive Intolerance, and Pancreatitis in Azathioprine-Treated Patients

Popis výsledku anglicky

Approximately 10-28 % of patients experience adverse drug reactions related to treatment with thiopurines. The most serious reaction is myelosuppression, typically manifested as leucopenia, which occurs in approximately 2-5 % of patients. Other adverse drug reactions that often accompany thiopurine therapy are pancreatitis, hepatotoxicity, allergic reactions, digestive intolerance, arthralgia, febrile conditions, and rash. The objective of this study was to assess the relationship between variant alleles of thiopurine S-methyltransferase (SNPs 238G } C, 460G } A and 719A } G), inosine triphosphate diphosphatase (SNPs 94C } A and IVS2 + 21A } C), and xanthine dehydrogenase (837C } T) and the occurrence of adverse drug reactions to azathioprine therapy.Genotype was determined for 188 Caucasians diagnosed with inflammatory bowel disease treated with a standard dose of azathioprine (1.4-2.0 mg/kg/day). Variant genotype thiopurine S-methyltransferase predisposes to development of leucopeni

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Digestive Diseases and Sciences

ISSN

0163-2116

e-ISSN

—

Svazek periodika

57

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

8

Strana od-do

2394-2401

Kód UT WoS článku

000308043300021

EID výsledku v databázi Scopus

—